A new meta-analysis indicates that multiple sclerosis disease-modifying therapies (DMTs) have positive effects on cognition. High-efficacy and medium-efficacy DMTs apparently had comparable cognitive benefits; however, limitations of the original studies, including brief duration, restricted assessment and failure to account for baseline cognitive impairment, might limit the interpretation of the findings.
Disease-modifying therapy aids cognition in multiple sclerosis / Amato, Maria Pia; Krupp, Lauren B. - In: NATURE REVIEWS. NEUROLOGY. - ISSN 1759-4758. - ELETTRONICO. - (2020), pp. 1-5. [10.1038/s41582-020-0383-x]
Disease-modifying therapy aids cognition in multiple sclerosis
Amato, Maria Pia;
2020
Abstract
A new meta-analysis indicates that multiple sclerosis disease-modifying therapies (DMTs) have positive effects on cognition. High-efficacy and medium-efficacy DMTs apparently had comparable cognitive benefits; however, limitations of the original studies, including brief duration, restricted assessment and failure to account for baseline cognitive impairment, might limit the interpretation of the findings.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.